Among these fusion proteins, Ec‐LDP‐Hr‐AE was generated specifically against EGFR and HER2,9 showing potent effectiveness in a variety of cancer cells and xenograft tumors of ovary and esophagus.10 In pancreatic cancer, EGFR is overexpressed and continually activated, suggesting that this tumor might be responsive to EGFR‐targeted therapies.11, 12 Several studies have demonstrated that therapeutic agents simultaneously targeting EGFR and HER2 are promising strategies for pancreatic cancer.13, 14, 15, 16. Here, ERBB2 is linked to familial pancreatic carcinoma.